MEAI
MEAI (5-methoxy-2-aminoindane or 5-MeO-AI or Chaperon) is a recreational drug and binge drinking prevention drug, first chemically described in 1980,[1][2] and first pharmacologically described in a peer reviewed paper in 2017 by David Nutt et al.,[3] followed by another in February 2018 which detailed pharmacokinetics, pharmacodynamics and metabolism of MEAI.[4] In 2018, a company in the United States began offering an MEAI-based drink called "Pace".[5]
![]() | |
Clinical data | |
---|---|
Other names | 5-MeO-AI; 2,3-Dihydro-5-methoxy-1H-Inden-2-amine |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C10H13NO |
Molar mass | 163.220 g·mol−1 |
3D model (JSmol) | |
| |
|
MEAI was an early candidate of alcohol replacement drugs that came to market during a late 2010s movement to replace alcohol with less-toxic alternatives spearheaded by British psychopharmacologist David Nutt. Though MEAI was made commercially available online in the United States as "Pace", Nutt's commercial efforts moved away from direct marketing of MEAI in favor of Alcarelle.[6]
References
- Sainsbury PD, Kicman AT, Archer RP, King LA, Braithwaite RA (2011). "Aminoindanes--the next wave of 'legal highs'?". Drug Testing and Analysis. 3 (7–8): 479–82. doi:10.1002/dta.318. PMID 21748859.
- Cannon JG, Perez JA, Pease JP, Long JP, Flynn JR, Rusterholz DB, Dryer SE (July 1980). "Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminotetralin, 2-aminoindan, and 6-aminobenzocycloheptene". Journal of Medicinal Chemistry. 23 (7): 745–9. doi:10.1021/jm00181a009. PMID 7190613.
- Shimshoni JA, Winkler I, Edery N, Golan E, van Wettum R, Nutt D (March 2017). "Toxicological evaluation of 5-methoxy-2-aminoindane (MEAI): Binge mitigating agent in development". Toxicology and Applied Pharmacology. 319: 59–68. doi:10.1016/j.taap.2017.01.018. PMID 28167221.
- Shimshoni JA, Sobol E, Golan E, Ben Ari Y, Gal O (March 2018). "Pharmacokinetic and pharmacodynamic evaluation of 5-methoxy-2-aminoindane (MEAI): A new binge-mitigating agent". Toxicology and Applied Pharmacology. 343: 29–39. doi:10.1016/j.taap.2018.02.009. PMID 29458138.
- Pace D. "Pace by DACOA". Pace. DACOA. Retrieved 12 August 2018.
- "Alcarelle". 19 August 2019.